Cornelia Bargmann - Astrazeneca PLC Non-Executive Director

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>AP</div>
AZN -- USA Stock  

Report: 30th of July 2020  

  Director
Dr. Cornelia Bargmann is a NonExecutive Director of the Company. She is the Torsten N. Wiesel Professor and head of the Lulu and Anthony Wang Laboratory of Neural Circuits and Behavior at The Rockefeller University New York. She was a Howard Hughes Medical Institute investigator since 1995. She is a neurobiologist who studies the relationships between genes neural circuits and behaviour using C. elegans a tiny roundworm as the model for her work. Many of the genes and neural pathways in C. elegans are similar to those of mammals and their study provides an insight into the development and functioning of neural circuits. Cori holds a degree in biochemistry from the University of Georgia and a Ph.D. from the Massachusetts Institute of Technology where she studied oncogenes with Robert Weinberg. She pursued a postdoctoral fellowship with H. Robert Horvitz at MIT until 1991 when she accepted a faculty position in the Department of Anatomy at the University of California San Francisco spending 13 years there latterly as ViceChair of the department. She took up her current position at The Rockefeller University in 2004. Cori is the recipient of the 2015 Benjamin Franklin Medal in Life Science one of nine individuals who will be presented with awards by The Franklin Institute Philadelphia this year. The award is for her contributions to neurobiology that have led to major discoveries elucidating the relationship between genes neurons neural circuits and behaviour.
  Director Since 2015  Ph.D    
(44) 1223 352 858  www.astrazeneca.com

Astrazeneca PLC Management Efficiency

Astrazeneca PLC has Return on Asset of 3.6 % which means that on every $100 spent on asset it made $3.6 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 11.66 %, implying that it generated $11.66 on every 100 dollars invested. Astrazeneca PLC management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. Return on Investment is projected to rise to 9.64 this year. Return on Average Assets is projected to rise to 0.0205 this yearAstrazeneca PLC Asset Turnover is quite stable at the moment as compared to the past year. The company's current value of Asset Turnover is estimated at about 0.41. Return on Average Assets is projected to rise to 0.0205 this year, although the value of Tax Assets will most likely fall to about 2.6 B. Astrazeneca PLC Total Liabilities is quite stable at the moment as compared to the past year. The company's current value of Total Liabilities is estimated at about 46.98 Billion. Current Liabilities is projected to rise to about 18.9 B this year, although the value of Liabilities Non Current will most likely fall to about 28.1 B.
The company has 20.98 B in debt with debt to equity (D/E) ratio of 1.72, which is OK given its current industry classification. Astrazeneca PLC has a current ratio of 0.74, suggesting that it has not enough short term capital to pay financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Jesse GoodmanGlaxoSmithKline PLC
2017
William HarrisonMerck Company
2009
Lewis CampbellBristol Myers Squibb
2014
Leslie BrunMerck Company
2016
Mark McClellanJohnson Johnson
2013
Cabot BrownGW Pharmaceuticals Plc
2013
Susan LindquistJohnson Johnson
2004
Steven MayerGrifols S A
2016
Nicholas MooreGilead Sciences
2004
Pamela CraigMerck Company
2015
Iain MackayGlaxoSmithKline PLC
2019
Thomas GlocerMerck Company
2007
Vindi BangaGlaxoSmithKline PLC
2017
Anna LluchGrifols S A
2008
Dinesh PaliwalBristol Myers Squibb
2013
Paul RothmanMerck Company
2015
Srikant DatarNovartis AG
2003
Ian DavisJohnson Johnson
2010
Kelly KramerGilead Sciences
2016
Brett IngersollGrifols S A
2011
Ralph AlvarezEli Lilly And
2009

Company Summary

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. Astrazeneca PLC operates under Drug ManufacturersGeneral classification in the United States and is traded on BATS Exchange. It employs 70600 people.Astrazeneca PLC (AZN) is traded on BATS Exchange in USA. It is located in 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom and employs 70,600 people. Astrazeneca PLC is listed under Pharmaceutical Products category by Fama And French industry classification.

Astrazeneca PLC Leadership Team

Marc Dunoyer, Chief Financial Officer, Executive Director
Sherilyn McCoy, Non-Executive Independent Director
Genevieve Berger, Non-Executive Independent Director
Luke Miels, Executive Vice-President GPPS
Sean Bohen, Chief Medical Officer, Executive Vice President - Global Medicines Development
Paul Hudson, Executive Vice President North America
Nazneen Rahman, Non-Executive Independent Director
Jose Baselga, Executive Vice President - Research & Development Oncology
JeanPhilippe Courtois, Non-Executive Independent Director
Thomas Larsen, IR Contact Officer
Katarina Ageborg, Executive Vice President - Sustainability, Chief Compliance Officer
Tony Mok, Non-Executive Independent Director
Mark Mallon, Executive Vice President International
Fiona Cicconi, Executive Vice President - Human Resources
Deborah DiSanzo, Non-Executive Independent Director
Shriti Vadera, Non-Executive Independent Director
Leif Johansson, Non-Executive Independent Chairman of the Board
Leon Wang, Executive Vice President - International and China President
Ann Cairns, Non-Executive Director
Adrian Kemp, Company Secretary
Cornelia Bargmann, Non-Executive Director
Tim JacksonSmith, Non-Executive Director
Michel Demare, Non-Executive Independent Director
Graham Chipchase, Senior Non-Executive Independent Director
David Smith, Executive VP of Operations and Information Services
Pascal Soriot, CEO, Executive Director and Member of Disclosure Committee
Pam Cheng, Executive Vice-President of Operations and Information Technology
Baroness Vadera, Non-Executive Independent Director
Philip Broadley, Non-Executive Independent Director
Narayan Seshadri, Independent Director
Jeffrey Pott, General Counsel
Ruud Dobber, Executive Vice President, BioPharmaceuticals Business
David Fredrickson, Executive Vice-President Global Head Oncology Business Unit
Bahija Jallal, Executive Vice President MedImmune
Rudolph Markham, Non-Executive Independent Director
Menelas Pangalos, Executive Vice President - Research & Development BioPharmaceuticals
Weiying Wang, Non-Executive Director
Bruce Burlington, Non-Executive Independent Director
Marcus Wallenberg, Non-Executive Director
Iskra Reic, Executive Vice President - Europe and Canada

Stock Performance Indicators

Current Sentiment - AZN

Astrazeneca PLC Investor Sentiment

Predominant part of Macroaxis users are presently bullish on Astrazeneca PLC. What is your sentiment towards investing in Astrazeneca PLC? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Astrazeneca PLC Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Astrazeneca PLC and Gilead Sciences. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Please continue to Trending Equities. Please also try Price Transformation module to use price transformation models to analyze depth of different equity instruments across global markets.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page